UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Prescription drug misuse: Epidemiology, prevention, identification, and management

Authors
William Becker, MD
Joanna L Starrels, MD, MS
Section Editor
Andrew J Saxon, MD
Deputy Editor
Richard Hermann, MD

INTRODUCTION

Opioid analgesics, benzodiazepines, other sedatives and tranquilizers, and stimulants have important medical uses, but they also stimulate the reward center of the brain. In susceptible individuals, this can lead to misuse, substance use disorders/addiction, and other serious consequences. It has led to the development of an illicit market for these medications.

Despite government regulation of these medications, prescription drug misuse and its consequences have persisted and increased. Physicians who prescribe these medications have an important role in reversing these trends.

This topic reviews the epidemiology, prevention, identification, and management of prescription drug misuse. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of opioid use disorder, benzodiazepine use disorder, and stimulant use disorder are discussed separately. (See "Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis" and "Pharmacotherapy for opioid use disorder" and "Methamphetamine use disorder: Epidemiology, clinical manifestations, course, assessment, and diagnosis" and "Cocaine use disorder in adults: Epidemiology, pharmacology, clinical manifestations, medical consequences, and diagnosis" and "Psychosocial interventions for stimulant use disorder in adults" and "Pharmacotherapy for stimulant use disorders in adults".)

TERMINOLOGY

Controlled substances — Because of their potential for misuse, addiction, and illicit diversion and sale, opioid analgesics, stimulants, and benzodiazepines and other sedatives/hypnotics are regulated, restricting whether and how they can be prescribed. In the US, these drugs are referred to as "controlled substances" and subject to Federal regulations (table 1).

Prescription drug misuse — Any use of a prescription medication that is outside of the manner and intent for which it was prescribed; this includes overuse, use to get high, diversion (sharing or selling to others), having multiple prescribers or nonprescribed sources of the medication, and concurrent use of alcohol, illicit substances, or nonprescribed controlled medications. Misuse is a necessary but not sufficient criterion for a substance use disorder.

                              

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Jun 09 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, in NSDUH Series H-44, HHS 2012. Rockville, MD 2012.
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
  3. Castle L, Aubert RE, Verbrugge RR, et al. Trends in medication treatment for ADHD. J Atten Disord 2007; 10:335.
  4. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007; 297:249.
  5. Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013. Am J Public Health 2016; 106:686.
  6. Von Korff M, Dublin S, Walker RL, et al. The Impact of Opioid Risk Reduction Initiatives on High-Dose Opioid Prescribing for Patients on Chronic Opioid Therapy. J Pain 2016; 17:101.
  7. Paulozzi LJ, Strickler GK, Kreiner PW, et al. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013. MMWR Surveill Summ 2015; 64:1.
  8. Fleming MF, Balousek SL, Klessig CL, et al. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007; 8:573.
  9. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006; 6:46.
  10. Reid MC, Engles-Horton LL, Weber MB, et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med 2002; 17:173.
  11. Morasco BJ, Dobscha SK. Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. Gen Hosp Psychiatry 2008; 30:93.
  12. Banta-Green CJ, Merrill JO, Doyle SR, et al. Measurement of opioid problems among chronic pain patients in a general medical population. Drug Alcohol Depend 2009; 104:43.
  13. Polatin PB, Kinney RK, Gatchel RJ, et al. Psychiatric illness and chronic low-back pain. The mind and the spine--which goes first? Spine (Phila Pa 1976) 1993; 18:66.
  14. Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004; 28:250.
  15. Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health, SAMHSA, Rockville 2015.
  16. Becker WC, Fiellin DA, Gallagher RM, et al. The association between chronic pain and prescription drug abuse in Veterans. Pain Med 2009; 10:531.
  17. Johnston LD, et al. Monitoring the Future national survey results on drug use, 1975-2012: Secondary school students 2013, Institute for Social Research, The University of Michigan, Ann Arbor Vol 1.
  18. Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 2010; 105:1776.
  19. Liebschutz JM, Saitz R, Weiss RD, et al. Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. J Pain 2010; 11:1047.
  20. Substance Abuse Treatment Admissions by Primary Substance of Abuse, According to Sex, Age Group, Race, and Ethnicity, 2013. http://wwwdasis.samhsa.gov/webt/quicklink/US13.htm (Accessed on June 02, 2016).
  21. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The TEDS Report: 2001-2011 National Admissions to Substance Abuse Treatment Services. 2013; Rockville, MD.
  22. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The TEDS Report: A Comparison of Rural and Urban Substance Abuse Treatment Admissions. Rockville, MD July 31, 2012.
  23. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates (Accessed on June 02, 2016).
  24. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309:657.
  25. Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study. Drug Alcohol Depend 2016; 160:127.
  26. Edlund MJ, Steffick D, Hudson T, et al. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain 2007; 129:355.
  27. Wasan AD, Butler SF, Budman SH, et al. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 2007; 23:307.
  28. Becker WC, Starrels JL, Heo M, et al. Racial differences in primary care opioid risk reduction strategies. Ann Fam Med 2011; 9:219.
  29. Vijayaraghavan M, Penko J, Guzman D, et al. Primary care providers’ judgments of opioid analgesic misuse in a community-based cohort of HIV-infected indigent adults. J Gen Intern Med 2011; 26:412.
  30. Chabal C, Erjavec MK, Jacobson L, et al. Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors. Clin J Pain 1997; 13:150.
  31. Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction 2012; 107:467.
  32. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47:21.
  33. Bogle KE, Smith BH. Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev 2009; 2:157.
  34. Substance Abuse and Mental Health Services Administration. The DAWN Report: Emergency Department Visits Involving Attention Deficit/Hyperactivity Disorder Stimulant Medications. Rockville, MD.
  35. Spiller HA, Hays HL, Aleguas A Jr. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 2013; 27:531.
  36. Looby A, De Young KP, Earleywine M. Challenging expectancies to prevent nonmedical prescription stimulant use: a randomized, controlled trial. Drug Alcohol Depend 2013; 132:362.
  37. Substance Abuse and Mental Health Services Administration. The TEDS Report: Admissions Reporting Benzodiazepine and Narcotic PainReliever Abuse at Treatment Entry. Rockville, MD 2012.
  38. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300:2613.
  39. Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ 2015; 350:h2698.
  40. Weisberg DF, Gordon KS, Barry DT, et al. Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. J Acquir Immune Defic Syndr 2015; 69:223.
  41. Becker WC, Fiellin DA, Desai RA. Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend 2007; 90:280.
  42. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113.
  43. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep 2016; 65:1.
  44. Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004; 112:65.
  45. Compton PA, Wu SM, Schieffer B, et al. Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement noncompliance. J Pain Symptom Manage 2008; 36:383.
  46. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005; 6:432.
  47. Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med 2010; 152:712.
  48. Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med 2012; 13:87.
  49. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152:85.
  50. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305:1315.
  51. Federation of State Medical Boards. Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain. 2013.
  52. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005; 6:107.
  53. Federation of State Medical Boards. Model policy for the use of controlled substances for the treatment of pain. 2004.
  54. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clin J Pain 1999; 15:184.
  55. Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003; 97:1097.
  56. Schuckman H, Hazelett S, Powell C, Steer S. A validation of self-reported substance use with biochemical testing among patients presenting to the emergency department seeking treatment for backache, headache, and toothache. Subst Use Misuse 2008; 43:589.
  57. Robinson-Papp J, Elliott K, Simpson DM, et al. Problematic prescription opioid use in an HIV-infected cohort: the importance of universal toxicology testing. J Acquir Immune Defic Syndr 2012; 61:187.
  58. Michna E, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain 2007; 23:173.
  59. Bronstein K PS, Munitz L, Leider H. Can clinicians accurately predict which patients are misusing their medications?. American Pain Society 30th Annual Scientific Meeting 2011; Austin, TX.
  60. Reisfield GM, Bertholf R, Barkin RL, et al. Urine drug test interpretation: what do physicians know? J Opioid Manag 2007; 3:80.
  61. Reisfield GM, Webb FJ, Bertholf RL, et al. Family physicians' proficiency in urine drug test interpretation. J Opioid Manag 2007; 3:333.
  62. Starrels JL, Fox AD, Kunins HV, Cunningham CO. They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med 2012; 27:1521.
  63. Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med 2012; 13:434.
  64. Maughan BC, Bachhuber MA, Mitra N, Starrels JL. Prescription monitoring programs and emergency department visits involving opioids, 2004-2011. Drug Alcohol Depend 2015; 156:282.
  65. Bachhuber MA, Maughan BC, Mitra N, et al. Prescription monitoring programs and emergency department visits involving benzodiazepine misuse: Early evidence from 11 United States metropolitan areas. Int J Drug Policy 2016; 28:120.
  66. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011; 12:747.